---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-010595"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:47:34.795548+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025

## Summary
- Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.
- Cash $3.5M at year-end; subsequent $5.4M raise; expects runway into Q3 2025.
- R&D $8.2M (+14%) and sales/marketing $4.0M (6x increase) due to FemBloc/FemaSeed launch.
- FemBloc received European approval; partnerships with CNY Fertility, HRC Fertility, Boston IVF for FemaSeed.
- CEO guides U.S. revenue to increase ~50% in Q1 2025 vs Q4 2024.

## SEC filing metadata
- accession: 0001140361-25-010595
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/0001140361-25-010595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/ef20046254_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-010595
- JSON: https://secwatch.observer/filing/0001140361-25-010595.json
- Plain text: https://secwatch.observer/filing/0001140361-25-010595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.